Cutera Resultados de beneficios anteriores

Pasado controles de criterios 0/6

Los beneficios de Cutera han disminuido a una tasa media anual de -39%, mientras que en la industria Medical Equipment los beneficios crecieron en un 13.5% anualmente. Los ingresos han ido creciendo a una tasa media de 9.9% al año.

Información clave

-39.0%

Tasa de crecimiento de los beneficios

-29.6%

Tasa de crecimiento del BPA

Crecimiento de la industria Medical Equipment	8.9%
Tasa de crecimiento de los ingresos	9.9%
Rentabilidad financiera	n/a
Margen neto	-71.0%
Próxima actualización de resultados	09 May 2024

Actualizaciones de resultados anteriores recientes

Recent updates

Revenues Working Against Cutera, Inc.'s (NASDAQ:CUTR) Share Price Following 35% Dive

Mar 14

Analysts Are More Bearish On Cutera, Inc. (NASDAQ:CUTR) Than They Used To Be

Aug 11

An Intrinsic Calculation For Cutera, Inc. (NASDAQ:CUTR) Suggests It's 48% Undervalued

Apr 19

Cutera, Inc. (NASDAQ:CUTR) Shares Could Be 49% Below Their Intrinsic Value Estimate

Sep 01

Cutera: The 'AviClear' Sign To Get Bullish

Jun 22

Cutera (NASDAQ:CUTR) Is Carrying A Fair Bit Of Debt

May 27

Returns On Capital Signal Tricky Times Ahead For Cutera (NASDAQ:CUTR)

Apr 22

Cutera: Gains Aren't Surprising After Acne Laser Therapy Cleared

Mar 31

What Does Cutera, Inc.'s (NASDAQ:CUTR) Share Price Indicate?

Feb 23

We Think Cutera (NASDAQ:CUTR) Can Stay On Top Of Its Debt

Jan 08

Revisiting Cutera

Dec 18

We Like These Underlying Return On Capital Trends At Cutera (NASDAQ:CUTR)

Nov 30

Is Cutera (NASDAQ:CUTR) A Risky Investment?

Sep 17

Desglose de ingresos y gastos
Beta

Cómo gana y gasta dinero Cutera. Basado en los últimos beneficios reportados, en base a los últimos doce meses (LTM).

Historial de beneficios e ingresos

NasdaqGS:CUTR Ingresos, gastos y beneficios (USD Millions)
Fecha	Ingresos	Beneficios	Gastos G+A	Gastos de I+D
31 Dec 23	212	-151	182	21
30 Sep 23	230	-113	175	22
30 Jun 23	247	-81	169	24
31 Mar 23	249	-92	156	25
31 Dec 22	252	-82	153	25
30 Sep 22	251	-78	147	27
30 Jun 22	245	-68	137	26
31 Mar 22	240	-13	126	24
31 Dec 21	231	2	110	22
30 Sep 21	216	8	98	19
30 Jun 21	197	7	91	16
31 Mar 21	165	-12	83	15
31 Dec 20	148	-24	84	14
30 Sep 20	150	-28	87	15
30 Jun 20	157	-29	93	15
31 Mar 20	178	-17	96	15
31 Dec 19	182	-12	95	15
30 Sep 19	175	-37	90	14
30 Jun 19	170	-35	84	14
31 Mar 19	165	-37	83	15
31 Dec 18	163	-31	79	14
30 Sep 18	165	18	78	14
30 Jun 18	162	25	75	15
31 Mar 18	156	29	71	13
31 Dec 17	151	30	66	13
30 Sep 17	142	11	61	12
30 Jun 17	134	7	58	12
31 Mar 17	125	4	57	11
31 Dec 16	118	3	55	11
30 Sep 16	110	0	53	11
30 Jun 16	103	-2	51	11
31 Mar 16	98	-3	49	11
31 Dec 15	95	-4	48	11
30 Sep 15	90	-8	48	11
30 Jun 15	86	-10	47	10
31 Mar 15	81	-11	45	10
31 Dec 14	78	-11	43	11
30 Sep 14	75	-9	42	10
30 Jun 14	73	-8	40	10
31 Mar 14	75	-6	39	10
31 Dec 13	75	-5	38	9
30 Sep 13	75	-3	37	9
30 Jun 13	77	-3	37	9

Ingresos de calidad: CUTR actualmente no es rentable.

Margen de beneficios creciente: CUTR actualmente no es rentable.

Análisis del flujo de caja libre vs. Beneficios

Análisis del crecimiento de los beneficios en el pasado

Tendencia de beneficios: CUTR no es rentable, y las pérdidas han aumentado en los últimos 5 años a un ritmo de 39% al año.

Acelerando crecimiento: No se puede comparar el crecimiento de los beneficios de CUTR en el último año con su promedio de 5 años, ya que actualmente no es rentable.

Beneficios vs. Industria: CUTR no es rentable, por lo que resulta difícil comparar el crecimiento de sus beneficios en el último año con el de la industria Medical Equipment (3.3%).

Rentabilidad financiera

Alta ROE: El pasivo de CUTR supera su activo, por lo que es difícil calcular su rentabilidad financiera.

Cutera Resultados de beneficios anteriores

Pasado controles de criterios 0/6

Información clave

Actualizaciones de resultados anteriores recientes

Cutera, Inc. to Report Q1, 2024 Results on May 09, 2024

Third quarter 2023 earnings: EPS and revenues miss analyst expectations

Cutera, Inc. to Report Q4, 2023 Results on Mar 21, 2024

Cutera, Inc. to Report Q3, 2023 Results on Nov 08, 2023

Second quarter 2023 earnings: EPS and revenues miss analyst expectations

Cutera, Inc. to Report Q2, 2023 Results on Aug 08, 2023

Recent updates

Cutera, Inc. to Report Q1, 2024 Results on May 09, 2024

Cutera, Inc. Announces North America Launch of xeo+

Cutera, Inc. Provides Revenue Guidance for the Full Year 2024

Cutera, Inc. announced delayed annual 10-K filing

Revenues Working Against Cutera, Inc.'s (NASDAQ:CUTR) Share Price Following 35% Dive

Consensus EPS estimates fall by 33%

Third quarter 2023 earnings: EPS and revenues miss analyst expectations

Cutera, Inc. to Report Q4, 2023 Results on Mar 21, 2024

Price target decreased by 59% to US$7.67

High number of new and inexperienced directors

Cutera, Inc. Revises Revenue Guidance for the Full Year 2023

Cutera, Inc. Receives Notification of Deficiency from Nasdaq Related to Delayed Annual Report on Form 10-Q

Cutera, Inc. announced delayed 10-Q filing

Cutera, Inc. Announces Resignation of Juliane Park from the Board of Directors, Effective as of December 1, 2023

Cutera, Inc. to Report Q3, 2023 Results on Nov 08, 2023

Janet Widmann Resigns from the Board of Directors of Cutera, Inc. Effective November 1, 2023

New minor risk - Market cap size

Cutera, Inc. Appoints Brent Hauser as President, International

Cutera, Inc. Announces the Launch of New Skin Resurfacing and Revitalization Platform Secret DUO

President recently bought US$297k worth of stock

Cutera, Inc. Appoints Jeffrey Jones as Chief Operating Officer, Effective August 28, 2023

Consensus revenue estimates fall by 14%

Analysts Are More Bearish On Cutera, Inc. (NASDAQ:CUTR) Than They Used To Be

New major risk - Share price stability

Second quarter 2023 earnings: EPS and revenues miss analyst expectations

Price target decreased by 8.9% to US$23.00

Cutera, Inc. Provides Revenue Guidance for the Full Year 2023

Cutera, Inc. Appoints Talyor C. Harris as President, Effective August 7, 2023

Cutera, Inc. Announces CEO Changes, Effective August 7, 2023

Cutera, Inc. to Report Q2, 2023 Results on Aug 08, 2023

the Gross Law Firm Notifies Shareholders of Cutera, Inc. of A Class Action Lawsuit and A Lead Plaintiff Deadline of July 24, 2023

Cutera, Inc. Announces A New U.S. Food and Drug Administration Clearance of AviClear as A Long-Term Treatment for Mild to Severe Inflammatory Acne Vulgaris

Cutera, Inc. Announces Resignation of J. Daniel Plants as Director

Independent Director notifies of intention to sell stock

Cutera, Inc. Announces Resignation of Joseph E. Whitters from the Board of Directors

Kessler Topaz Meltzer & Check, LLP Files a Securities Fraud Class Action Lawsuit Against Cutera, Inc

Less than half of directors are independent

Cutera, Inc. Announces Board Changes

Cutera, Inc. Appoints Stuart Drummond as Interim Chief Financial Officer

Voce Capital and David Mowry Terminate Proxy Solicitation

Cutera, Inc. Announces Chief Financial Officer Changes

First quarter 2023 earnings: EPS and revenues miss analyst expectations

An Intrinsic Calculation For Cutera, Inc. (NASDAQ:CUTR) Suggests It's 48% Undervalued

Full year 2022 earnings: EPS misses analyst expectations

Consensus EPS estimates fall by 57%

Now 21% undervalued after recent price drop

Full year 2022 earnings: EPS misses analyst expectations

Does Cutera (NASDAQ:CUTR) Have A Healthy Balance Sheet?

Price target decreased to US$61.20

Cutera, Inc. to Report Q4, 2022 Results on Feb 28, 2023

Cutera, Inc. Announces AviClear™ Now Broadly Available to US Physicians and Practitioners Upon National Launch

Third quarter 2022 earnings released: US$0.62 loss per share (vs US$0.077 loss in 3Q 2021)

Cutera, Inc. Reiterates Revenue Guidance for the Full Year of 2022

Cutera, Inc. Announces Committee Appointments

Cutera, Inc. to Report Q3, 2022 Results on Nov 03, 2022

Would Cutera (NASDAQ:CUTR) Be Better Off With Less Debt?

Cutera, Inc. Announces Resignation of Katherine S. Zanotti from the Board

Cutera: Shares Very Attractively Priced, Top-Line Hedged From CMS

Cutera, Inc. (NASDAQ:CUTR) Shares Could Be 49% Below Their Intrinsic Value Estimate

Cutera, Inc. Reiterates Revenue Guidance for the Full Year of 2022

Second quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Cutera, Inc. to Report Q2, 2022 Results on Aug 04, 2022

Cutera, Inc. Announces AviClear Secured Clearance from Health Canada

Cutera: The 'AviClear' Sign To Get Bullish

Cutera (NASDAQ:CUTR) Is Carrying A Fair Bit Of Debt

Cutera, Inc. Reiterates Revenue Guidance for the Full Year of 2022

First quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Consensus forecasts updated

Cutera, Inc., Annual General Meeting, Jun 15, 2022

Desglose de ingresos y gastos
Beta